• 5/25/2006
  • Durham, NC
  • Lee W.T. Alkureishi et al.
  • The Oncologist, Vol. 11, No. 5, 469-480, May 2006

Head and neck cancer frequently presents at a late stage, leading to a poor prognosis despite optimal treatment with surgery and/or radiotherapy. Chemotherapy for advanced disease has shown little benefit as a single-modality treatment, and the use of concurrent chemoradiation is limited by problems with severe toxicity at higher doses.

RADPLAT is the acronym used to describe a new technique, combining intra-arterial delivery of cisplatin with systemic neutralization by i.v. sodium thiosulphate, and concurrent radiotherapy. This allows very high cisplatin dose intensities to be used while potentially minimizing adverse systemic effects.

Initial results suggest that excellent locoregional control rates are achievable in patients with unresectable disease, with a favorable side-effect profile when compared with conventional chemoradiation protocols. In addition, RADPLAT may potentially be of benefit in selected patients with resectable disease, allowing for preservation of organ function and quality of life without compromising locoregional control or survival.

While current phase II data are encouraging, phase III randomized controlled trials are required in order to directly compare RADPLAT with i.v. chemoradiation therapy, the current standard of care. This article reviews the evolution of the RADPLAT concept, from initial clinical trials to its current application in the treatment of patients with advanced head and neck cancer.

Note: The full text of the article is available here

Lee W.T. Alkureishi(a), Remco de Bree(b), Gary L. Ross(c)

Authors’ affiliations:
a Department of Plastic Surgery, Canniesburn Hospital, Glasgow Royal Infirmary, Glasgow, United Kingdom;
b Department of Otolaryngology/Head and Neck Surgery, VU University Medical Center, Amsterdam, The Netherlands;
c Department of Plastic Surgery, Christie Hospital, Manchester, United Kingdom

Print Friendly, PDF & Email